首页 > 最新文献

Federal practitioner : for the health care professionals of the VA, DoD, and PHS最新文献

英文 中文
Catheter-Directed Retrieval of an Infected Fragment in a Vietnam War Veteran. 越战老兵体内感染碎片的导管定向提取。
Ahmed Elgazzar, Abeer Chaudhary, Lance Klosterman

Background: Shrapnel injuries are commonly encountered in war zones. The severity of these injuries depends on the initial damage and both the anatomical and immune response at the time of injury or at more remote times in the case of reactivation.

Case presentation: A veteran sustained a shrapnel injury to his left lower abdomen while serving in the Vietnam War. Nearly 50 years later, the patient presented with a recurrent retroperitoneal abscess associated with a residual fragment. In cooperation between interventional radiology and surgery, traditional endovascular techniques and devices were used to relocate an extravascular, secondarily infected fragment to an area more suitable for a minor surgical approach in the left inguinal region. Subsequent surgical excision and removal required only a superficial incision as opposed to a large retroperitoneal dissection, minimizing recovery time and allowing quick and full healing of the patient.

Conclusions: This case demonstrates a multidisciplinary approach to transforming an otherwise large retroperitoneal dissection to a minimally invasive and technically efficient abscess drainage and foreign body retrieval.

背景:弹片伤在战区很常见。这些损伤的严重程度取决于初始损伤以及损伤时的解剖和免疫反应,或者在更遥远的时间内重新激活。案例介绍:一名退伍军人在越南战争中被弹片击中左下腹。近50年后,患者再次出现腹膜后脓肿并伴有残余碎片。在介入放射学和外科的合作下,使用传统的血管内技术和设备将血管外继发感染碎片重新定位到更适合左腹股沟区域的小手术入路的区域。随后的手术切除和移除只需要一个浅表切口,而不是一个大的腹膜后剥离,最大限度地减少了恢复时间,并允许患者快速和完全愈合。结论:本病例展示了一种多学科的方法将腹膜后巨大的夹层转化为微创和技术上有效的脓肿引流和异物取出。
{"title":"Catheter-Directed Retrieval of an Infected Fragment in a Vietnam War Veteran.","authors":"Ahmed Elgazzar,&nbsp;Abeer Chaudhary,&nbsp;Lance Klosterman","doi":"10.12788/fp.0312","DOIUrl":"https://doi.org/10.12788/fp.0312","url":null,"abstract":"<p><strong>Background: </strong>Shrapnel injuries are commonly encountered in war zones. The severity of these injuries depends on the initial damage and both the anatomical and immune response at the time of injury or at more remote times in the case of reactivation.</p><p><strong>Case presentation: </strong>A veteran sustained a shrapnel injury to his left lower abdomen while serving in the Vietnam War. Nearly 50 years later, the patient presented with a recurrent retroperitoneal abscess associated with a residual fragment. In cooperation between interventional radiology and surgery, traditional endovascular techniques and devices were used to relocate an extravascular, secondarily infected fragment to an area more suitable for a minor surgical approach in the left inguinal region. Subsequent surgical excision and removal required only a superficial incision as opposed to a large retroperitoneal dissection, minimizing recovery time and allowing quick and full healing of the patient.</p><p><strong>Conclusions: </strong>This case demonstrates a multidisciplinary approach to transforming an otherwise large retroperitoneal dissection to a minimally invasive and technically efficient abscess drainage and foreign body retrieval.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"39 9","pages":"372-375"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794165/pdf/fp-39-09-372.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma. 2例多发性骨髓瘤患者同时发生卡非佐米诱发的血栓性微血管病变。
Nathaniel J Myall, Samantha X Wang, Evan T Hall, Wesley H Witteles, Lawrence Leung, Tamara J Dunn, Wan-Jen Hong

Background: In patients with multiple myeloma, thrombotic microangiopathy is a rare adverse event associated with proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib.

Case presentation: Two patients with multiple myeloma who presented with carfilzomib-induced thrombotic microangiopathy received eculizumab with subsequent stabilization of renal function.

Conclusions: Given the overall rarity of this adverse event, the simultaneous presentation of these 2 cases was unexpected. These cases underscores the need for heightened awareness in clinical practice of thrombotic microangiopathy. The potential role of eculizumab as a therapeutic treatment in the setting of thrombotic microangiopathy requires further investigation.

背景:在多发性骨髓瘤患者中,血栓性微血管病变是与蛋白酶体抑制剂(如硼替佐米、卡非佐米和伊沙唑米)相关的罕见不良事件。病例介绍:两名多发性骨髓瘤患者出现卡非佐米诱发的血栓性微血管病变,他们接受了eculizumab治疗,随后肾功能稳定。结论:考虑到这种不良事件的总体罕见性,这2例同时出现是出乎意料的。这些病例强调在临床实践中需要提高对血栓性微血管病的认识。eculizumab在血栓性微血管病治疗中的潜在作用需要进一步研究。
{"title":"Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.","authors":"Nathaniel J Myall,&nbsp;Samantha X Wang,&nbsp;Evan T Hall,&nbsp;Wesley H Witteles,&nbsp;Lawrence Leung,&nbsp;Tamara J Dunn,&nbsp;Wan-Jen Hong","doi":"10.12788/fp.0284","DOIUrl":"https://doi.org/10.12788/fp.0284","url":null,"abstract":"<p><strong>Background: </strong>In patients with multiple myeloma, thrombotic microangiopathy is a rare adverse event associated with proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib.</p><p><strong>Case presentation: </strong>Two patients with multiple myeloma who presented with carfilzomib-induced thrombotic microangiopathy received eculizumab with subsequent stabilization of renal function.</p><p><strong>Conclusions: </strong>Given the overall rarity of this adverse event, the simultaneous presentation of these 2 cases was unexpected. These cases underscores the need for heightened awareness in clinical practice of thrombotic microangiopathy. The potential role of eculizumab as a therapeutic treatment in the setting of thrombotic microangiopathy requires further investigation.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"39 Suppl 3","pages":"S56-S62"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662305/pdf/fp-39-08s-s56.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9340287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis. 长时间药物致过敏综合征/DRESS伴斑秃和自身免疫性甲状腺炎。
Pub Date : 2022-08-01 Epub Date: 2022-08-11 DOI: 10.12788/fp.0289
Lt Kathleen Krivda, Ltc John Campagna, Maj Salvatore Mignano, Col Sunghun Cho

Background: Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multiorgan involvement, viral reactivation, and hematologic abnormalities.

Case presentation: We present a case of lamotrigine-associated DIHS/DRESS complicated by an unusually prolonged course requiring oral corticosteroids and narrow-band ultraviolet B treatment and with development of extensive alopecia areata and autoimmune thyroiditis.

Conclusions: DIHS/DRESS is a severe cutaneous adverse reaction that may require prolonged treatment until symptoms resolve. Oral corticosteroids are the mainstay of treatment, but long-term use is associated with significant adverse effects. Alternative therapies, such as cyclosporine, look promising, but further studies are needed to determine safety profile and efficacy. DIHS/DRESS patients also should be educated and followed for potential autoimmune sequelae.

背景:药物性超敏反应综合征(DIHS),也称为嗜酸性粒细胞增多和全身症状的药物反应(DRESS)综合征,是一种潜在致命的药物性超敏反应,其特征是皮肤出疹、多器官受累、病毒再激活和血液学异常。病例介绍:我们报告了一例拉莫三嗪相关的DIHS/DRESS并发异常延长的病程,需要口服皮质类固醇和窄带紫外线B治疗,并发展为广泛的斑秃和自身免疫性甲状腺炎。结论:DIHS/DRESS是一种严重的皮肤不良反应,可能需要长期治疗直至症状消退。口服皮质类固醇是主要的治疗方法,但长期使用会产生显著的不良反应。替代疗法,如环孢素,看起来很有希望,但需要进一步的研究来确定安全性和有效性。DIHS/DRESS患者也应接受教育并随访潜在的自身免疫性后遗症。
{"title":"Prolonged Drug-Induced Hypersensitivity Syndrome/DRESS With Alopecia Areata and Autoimmune Thyroiditis.","authors":"Lt Kathleen Krivda,&nbsp;Ltc John Campagna,&nbsp;Maj Salvatore Mignano,&nbsp;Col Sunghun Cho","doi":"10.12788/fp.0289","DOIUrl":"https://doi.org/10.12788/fp.0289","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced hypersensitivity syndrome (DIHS), also called drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is a potentially fatal drug-induced hypersensitivity reaction that is characterized by a cutaneous eruption, multiorgan involvement, viral reactivation, and hematologic abnormalities.</p><p><strong>Case presentation: </strong>We present a case of lamotrigine-associated DIHS/DRESS complicated by an unusually prolonged course requiring oral corticosteroids and narrow-band ultraviolet B treatment and with development of extensive alopecia areata and autoimmune thyroiditis.</p><p><strong>Conclusions: </strong>DIHS/DRESS is a severe cutaneous adverse reaction that may require prolonged treatment until symptoms resolve. Oral corticosteroids are the mainstay of treatment, but long-term use is associated with significant adverse effects. Alternative therapies, such as cyclosporine, look promising, but further studies are needed to determine safety profile and efficacy. DIHS/DRESS patients also should be educated and followed for potential autoimmune sequelae.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"350-354"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652029/pdf/fp-39-08-350.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40486167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Establishing a Hospital Artificial Intelligence Committee to Improve Patient Care. 成立医院人工智能委员会,改善患者护理。
Pub Date : 2022-08-01 Epub Date: 2022-08-10 DOI: 10.12788/fp.0299
Andrew A Borkowski, Colleen E Jakey, L Brannon Thomas, Narayan Viswanadhan, Stephen M Mastorides

Background: The use of artificial intelligence (AI) in health care is increasing and has shown utility in many medical specialties, especially pathology, radiology, and oncology.

Observations: Many barriers exist to successfully implement AI programs in the clinical setting. To address these barriers, a formal governing body, the hospital AI Committee, was created at James A. Haley Veterans' Hospital in Tampa, Florida. The AI committee reviews and assesses AI products based on their success at protecting human autonomy; promoting human well-being and safety and the public interest; ensuring transparency, explainability, and intelligibility; fostering responsibility and accountability; ensuring inclusiveness and equity; and promoting AI that is responsive and sustainable.

Conclusions: Through the hospital AI Committee, we may overcome many obstacles to successfully implementing AI applications in the clinical setting.

背景:人工智能(AI)在医疗保健中的应用正在增加,并在许多医学专业,特别是病理学、放射学和肿瘤学中显示出实用性。观察结果:在临床环境中成功实施人工智能项目存在许多障碍。为了解决这些障碍,佛罗里达州坦帕市的詹姆斯·a·哈利退伍军人医院成立了一个正式的管理机构——医院人工智能委员会。人工智能委员会根据人工智能产品在保护人类自主性方面的成功程度,对其进行审查和评估;促进人类福祉、安全和公众利益;确保透明度、可解释性和可理解性;培养责任感和问责制;确保包容和公平;促进具有响应性和可持续性的人工智能。结论:通过医院人工智能委员会,我们可以克服许多障碍,成功地在临床环境中实施人工智能应用。
{"title":"Establishing a Hospital Artificial Intelligence Committee to Improve Patient Care.","authors":"Andrew A Borkowski,&nbsp;Colleen E Jakey,&nbsp;L Brannon Thomas,&nbsp;Narayan Viswanadhan,&nbsp;Stephen M Mastorides","doi":"10.12788/fp.0299","DOIUrl":"https://doi.org/10.12788/fp.0299","url":null,"abstract":"<p><strong>Background: </strong>The use of artificial intelligence (AI) in health care is increasing and has shown utility in many medical specialties, especially pathology, radiology, and oncology.</p><p><strong>Observations: </strong>Many barriers exist to successfully implement AI programs in the clinical setting. To address these barriers, a formal governing body, the hospital AI Committee, was created at James A. Haley Veterans' Hospital in Tampa, Florida. The AI committee reviews and assesses AI products based on their success at protecting human autonomy; promoting human well-being and safety and the public interest; ensuring transparency, explainability, and intelligibility; fostering responsibility and accountability; ensuring inclusiveness and equity; and promoting AI that is responsive and sustainable.</p><p><strong>Conclusions: </strong>Through the hospital AI Committee, we may overcome many obstacles to successfully implementing AI applications in the clinical setting.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"334-336"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652023/pdf/fp-39-08-334.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40511153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans. 退伍军人中的橙剂暴露、从 MGUS 转变为多发性骨髓瘤的过程和结果。
Pub Date : 2022-08-01 Epub Date: 2022-08-15 DOI: 10.12788/fp.0303
Jyothi Dodlapati, James A Hall, Pruthali Kulkarni, Kelsey B Reely, Amit A Nangrani, Laurel A Copeland

Background: Multiple myeloma (MM) accounts for 1% to 2% of all cancers. Exposure to the pesticide Agent Orange (AO) has been established as a potential risk factor for the development of monoclonal gammopathy of undetermined significance (MGUS) and, subsequently, MM in Vietnam War veterans.

Methods: This study explored variation in survival related to AO exposure, transformation from MGUS to MM, and covariates. Vietnam War veterans with MM or MGUS were identified in Veterans Health Administration (VHA) health records data. Cox proportional hazards models analyzed survival as a function of AO, race, ethnicity, body mass index, nicotine dependence, alcohol use disorder, Charlson Comorbidity Index, and treatment. Autologous hematopoietic cell transplantation for MM was defined by procedure codes.

Results: In the VHA 16,366 patients were identified: 11,112 patients diagnosed with MGUS and 7261 with MM during fiscal years 2010 to 2015 were identified; 12% (n = 2007) had both diagnoses. No statistically significant difference in the rate of transformation from MGUS to MM in the AO exposed and AO not exposed groups was found. In survival models, AO exposure was associated with slightly lower mortality. Alcohol use disorder, nicotine dependence, older age, and greater comorbidity burden increased mortality risk. Black race, female sex, obesity/overweight, and hematopoietic cell transplantation for patients with MM were protective factors. AO exposure was associated with decreased mortality for both MM/MGUS groups. Transformation increased mortality risk for patients with MGUS and decreased mortality risk for patients with MM.

Conclusions: Because AO exposure is a nonmodifiable risk factor, focus should be placed on modifiable risk factors (eg, nicotine dependence, alcohol and drug use disorders, underlying comorbid conditions) as these were associated with worse outcomes. Future studies should examine the correlation of AO exposure, cytogenetics, and clinical outcomes in these veterans to best identify their disease course and optimize their care in the latter part of their life.

背景:多发性骨髓瘤(MM多发性骨髓瘤(MM)占所有癌症的 1%至 2%。暴露于杀虫剂橙剂(AO)已被确定为越战老兵发生意义未定的单克隆丙种球蛋白病(MGUS)以及随后发生多发性骨髓瘤的潜在风险因素:本研究探讨了与暴露于 AO、从 MGUS 转化为 MM 以及协变量有关的存活率变化。从退伍军人健康管理局(VHA)的健康记录数据中确定了患有MM或MGUS的越战退伍军人。Cox比例危险模型分析了存活率与AO、种族、民族、体重指数、尼古丁依赖、酒精使用障碍、Charlson合并症指数和治疗的关系。治疗 MM 的自体造血细胞移植由手术代码定义:结果:在美国退伍军人协会(VHA)中发现了 16,366 名患者:2010至2015财年期间,有11112名患者被诊断为MGUS,7261名患者被诊断为MM;12%的患者(n = 2007)同时被诊断为这两种疾病。暴露于氧化亚氮组和未暴露于氧化亚氮组从 MGUS 转化为 MM 的比率在统计学上没有发现明显差异。在生存模型中,暴露于氧化亚氮与稍低的死亡率相关。酗酒、尼古丁依赖、年龄较大和合并症较多增加了死亡风险。黑种人、女性、肥胖/超重和 MM 患者接受造血细胞移植是保护因素。接触 AO 与 MM/MGUS 两组死亡率的降低有关。转化增加了MGUS患者的死亡风险,降低了MM患者的死亡风险:结论:由于暴露于 AO 是一种不可改变的风险因素,因此应重点关注可改变的风险因素(如尼古丁依赖、酒精和药物使用障碍、潜在的合并症),因为这些因素与较差的预后相关。未来的研究应检查这些退伍军人的AO暴露、细胞遗传学和临床结果之间的相关性,以最好地确定他们的病程并优化他们后半生的护理。
{"title":"Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans.","authors":"Jyothi Dodlapati, James A Hall, Pruthali Kulkarni, Kelsey B Reely, Amit A Nangrani, Laurel A Copeland","doi":"10.12788/fp.0303","DOIUrl":"10.12788/fp.0303","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma (MM) accounts for 1% to 2% of all cancers. Exposure to the pesticide Agent Orange (AO) has been established as a potential risk factor for the development of monoclonal gammopathy of undetermined significance (MGUS) and, subsequently, MM in Vietnam War veterans.</p><p><strong>Methods: </strong>This study explored variation in survival related to AO exposure, transformation from MGUS to MM, and covariates. Vietnam War veterans with MM or MGUS were identified in Veterans Health Administration (VHA) health records data. Cox proportional hazards models analyzed survival as a function of AO, race, ethnicity, body mass index, nicotine dependence, alcohol use disorder, Charlson Comorbidity Index, and treatment. Autologous hematopoietic cell transplantation for MM was defined by procedure codes.</p><p><strong>Results: </strong>In the VHA 16,366 patients were identified: 11,112 patients diagnosed with MGUS and 7261 with MM during fiscal years 2010 to 2015 were identified; 12% (n = 2007) had both diagnoses. No statistically significant difference in the rate of transformation from MGUS to MM in the AO exposed and AO not exposed groups was found. In survival models, AO exposure was associated with slightly lower mortality. Alcohol use disorder, nicotine dependence, older age, and greater comorbidity burden increased mortality risk. Black race, female sex, obesity/overweight, and hematopoietic cell transplantation for patients with MM were protective factors. AO exposure was associated with decreased mortality for both MM/MGUS groups. Transformation increased mortality risk for patients with MGUS and decreased mortality risk for patients with MM.</p><p><strong>Conclusions: </strong>Because AO exposure is a nonmodifiable risk factor, focus should be placed on modifiable risk factors (eg, nicotine dependence, alcohol and drug use disorders, underlying comorbid conditions) as these were associated with worse outcomes. Future studies should examine the correlation of AO exposure, cytogenetics, and clinical outcomes in these veterans to best identify their disease course and optimize their care in the latter part of their life.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"S23-S29a"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662308/pdf/fp-39-08s-s23.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40706823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Race on Outcomes in Veterans With Hepatocellular Carcinoma at a Single Center. 种族对退伍军人肝细胞癌预后的影响
Pub Date : 2022-08-01 Epub Date: 2022-08-13 DOI: 10.12788/fp.0304
Jackson Reynolds, Sarah Hashimi, Ngan Nguyen, Jordan Infield, Alva Weir, Amna Khattak

Background: Black patients have a higher incidence and mortality associated with hepatocellular carcinoma (HCC) compared with that of White patients in many retrospective analyses. This study sought to determine whether veterans treated for HCC at the Memphis Veterans Affairs Medical Center (VAMC) in Tennessee showed similar disparities in terms of stage at diagnosis, type of therapy received, and overall survival (OS).

Methods: A retrospective review evaluated 132 White and 95 Black patients treated for HCC between 2009 and 2021. We evaluated the impact on OS of age, sex, comorbidities, tumor stage, α-fetoprotein level, method of diagnosis, first-line treatment, systemic treatment, and surgical options offered. Kaplan-Meier analysis was used to investigate differences in OS and cumulative hazard ratio for death. Cox regression multivariate analysis evaluated discrepancies among investigated variables.

Results: The study found no significant difference in OS between Black and White veterans with HCC. Significant differences were found in who received surgical treatment and systemic therapy. More White veterans received any form of treatment compared with Black veterans (P < .001), and White veterans were more likely to undergo surgical resection and transplant (P = .052). There was no significant difference between age or stage at diagnosis, receipt of systemic therapy, alcohol, tobacco or drug use, HIV coinfection, or cirrhosis.

Conclusions: Black veterans with HCC at the Memphis VAMC were less likely to receive any form of treatment, surgical resection, or transplant compared with White veterans, but this did not have a statistically significant effect on OS.

背景:在许多回顾性分析中,与白人患者相比,黑人患者与肝细胞癌(HCC)相关的发病率和死亡率更高。本研究旨在确定在田纳西州孟菲斯退伍军人事务医疗中心(VAMC)接受HCC治疗的退伍军人在诊断阶段、接受的治疗类型和总生存期(OS)方面是否存在类似的差异。方法:回顾性分析了2009年至2021年间接受HCC治疗的132名白人和95名黑人患者。我们评估了年龄、性别、合并症、肿瘤分期、α-胎蛋白水平、诊断方法、一线治疗、全身治疗和手术选择等因素对OS的影响。Kaplan-Meier分析用于调查OS和死亡累积风险比的差异。Cox回归多变量分析评估了调查变量之间的差异。结果:研究发现黑人和白人退伍军人HCC患者的OS无显著差异。接受手术治疗和全身治疗的患者有显著差异。与黑人退伍军人相比,白人退伍军人接受任何形式的治疗的人数更多(P < 0.001),白人退伍军人更有可能接受手术切除和移植(P = 0.052)。年龄或诊断阶段、接受全身治疗、酒精、烟草或药物使用、HIV合并感染或肝硬化之间无显著差异。结论:与白人退伍军人相比,孟菲斯VAMC患有HCC的黑人退伍军人接受任何形式的治疗、手术切除或移植的可能性较小,但这对OS没有统计学意义上的显著影响。
{"title":"The Effect of Race on Outcomes in Veterans With Hepatocellular Carcinoma at a Single Center.","authors":"Jackson Reynolds,&nbsp;Sarah Hashimi,&nbsp;Ngan Nguyen,&nbsp;Jordan Infield,&nbsp;Alva Weir,&nbsp;Amna Khattak","doi":"10.12788/fp.0304","DOIUrl":"https://doi.org/10.12788/fp.0304","url":null,"abstract":"<p><strong>Background: </strong>Black patients have a higher incidence and mortality associated with hepatocellular carcinoma (HCC) compared with that of White patients in many retrospective analyses. This study sought to determine whether veterans treated for HCC at the Memphis Veterans Affairs Medical Center (VAMC) in Tennessee showed similar disparities in terms of stage at diagnosis, type of therapy received, and overall survival (OS).</p><p><strong>Methods: </strong>A retrospective review evaluated 132 White and 95 Black patients treated for HCC between 2009 and 2021. We evaluated the impact on OS of age, sex, comorbidities, tumor stage, α-fetoprotein level, method of diagnosis, first-line treatment, systemic treatment, and surgical options offered. Kaplan-Meier analysis was used to investigate differences in OS and cumulative hazard ratio for death. Cox regression multivariate analysis evaluated discrepancies among investigated variables.</p><p><strong>Results: </strong>The study found no significant difference in OS between Black and White veterans with HCC. Significant differences were found in who received surgical treatment and systemic therapy. More White veterans received any form of treatment compared with Black veterans (<i>P</i> < .001), and White veterans were more likely to undergo surgical resection and transplant (<i>P</i> = .052). There was no significant difference between age or stage at diagnosis, receipt of systemic therapy, alcohol, tobacco or drug use, HIV coinfection, or cirrhosis.</p><p><strong>Conclusions: </strong>Black veterans with HCC at the Memphis VAMC were less likely to receive any form of treatment, surgical resection, or transplant compared with White veterans, but this did not have a statistically significant effect on OS.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"S64-S67a"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662307/pdf/fp-39-08s-s64.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40706882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of a Pharmacy-Adjudicated Community Care Prior Authorization Drug Request Service. 药商裁定的社区护理预先授权药物请求服务的价值。
Pub Date : 2022-08-01 Epub Date: 2022-08-15 DOI: 10.12788/fp.0296
Andrew J Jennings, Jamie N Brown, Rachel B Britt, Leigh A McNaughton, Melissa Durkee, Mohamed G Hashem

Background: Many veterans are eligible to receive prescriptions from community-based pharmacies. Swift and accurate review of prior authorization drug requests by the US Department of Veterans Affairs (VA) pharmacy is necessary to mitigate treatment delays, medication misuse, adverse drug events, medication errors, and unnecessary cost to the health care system.

Methods: We performed a retrospective review of community care prior authorization drug requests to assess the direct cost savings achieved through a centralized process and to characterize submitted requests.

Results: The centralized community care pharmacy team demonstrated a cost savings of $515,872.31 over 6 months and increased patient safety. Community care prior authorization drug requests had a 46.2% approval rate. Coordination of care took an average of 8 days.

Conclusions: Use of a centralized community care pharmacy team could result in significant annual cost savings for the VA. Considering the approval rate seen in this study, VA could allocate resources to educate community-based prescribers about its formulary to increase the approval rate and reduce administrative burden for VA pharmacies and prescribers.

背景:许多退伍军人有资格从社区药房获得处方。美国退伍军人事务部(VA)药房对事先授权的药物请求进行迅速而准确的审查,对于减轻治疗延误、药物滥用、药物不良事件、药物错误和医疗保健系统的不必要成本是必要的。方法:我们对社区护理预先授权药物申请进行回顾性审查,以评估通过集中流程实现的直接成本节约,并对提交的申请进行特征分析。结果:集中社区护理药房团队在6个月内节省了515,872.31美元的成本,并提高了患者的安全性。社区护理预先授权药品申请的通过率为46.2%。协调护理平均需要8天。结论:使用集中的社区护理药房团队可以为VA节省大量的年度成本。考虑到本研究中看到的批准率,VA可以分配资源来教育社区处方者其处方,以提高批准率并减轻VA药房和处方者的行政负担。
{"title":"Value of a Pharmacy-Adjudicated Community Care Prior Authorization Drug Request Service.","authors":"Andrew J Jennings,&nbsp;Jamie N Brown,&nbsp;Rachel B Britt,&nbsp;Leigh A McNaughton,&nbsp;Melissa Durkee,&nbsp;Mohamed G Hashem","doi":"10.12788/fp.0296","DOIUrl":"https://doi.org/10.12788/fp.0296","url":null,"abstract":"<p><strong>Background: </strong>Many veterans are eligible to receive prescriptions from community-based pharmacies. Swift and accurate review of prior authorization drug requests by the US Department of Veterans Affairs (VA) pharmacy is necessary to mitigate treatment delays, medication misuse, adverse drug events, medication errors, and unnecessary cost to the health care system.</p><p><strong>Methods: </strong>We performed a retrospective review of community care prior authorization drug requests to assess the direct cost savings achieved through a centralized process and to characterize submitted requests.</p><p><strong>Results: </strong>The centralized community care pharmacy team demonstrated a cost savings of $515,872.31 over 6 months and increased patient safety. Community care prior authorization drug requests had a 46.2% approval rate. Coordination of care took an average of 8 days.</p><p><strong>Conclusions: </strong>Use of a centralized community care pharmacy team could result in significant annual cost savings for the VA. Considering the approval rate seen in this study, VA could allocate resources to educate community-based prescribers about its formulary to increase the approval rate and reduce administrative burden for VA pharmacies and prescribers.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"356-360a"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652025/pdf/fp-39-08-356.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40486169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting. 种族对高危前列腺癌患者在平等准入条件下接受中度低分割放疗的影响
Pub Date : 2022-08-01 Epub Date: 2022-08-15 DOI: 10.12788/fp.0305
David J Carpenter, Divya Natesan, R Warren Floyd, Taofik Oyekunle, Donna Niedzwiecki, Laura Waters, Devon Godfrey, Michael J Moravan, Rhonda L Bitting, Jeffrey R Gingrich, W Robert Lee, Joseph K Salama

Background: Moderately hypofractionated radiotherapy (MHRT) is an accepted treatment for localized prostate cancer; however, limited MHRT data address high-risk prostate cancer (HRPC) and/or African American patients. We report clinical outcomes and toxicity profiles for individuals with HRPC treated in an equal access system.

Methods: We identified patients with HRPC treated with MHRT at a US Department of Veterans Affairs referral center. Exclusion criteria included < 12 months follow-up and elective nodal irradiation. MHRT included 70 Gy over 28 fractions or 60 Gy over 20 fractions. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicities were graded using Common Terminology Criteria for Adverse Events, version 5.0. Clinical endpoints, including biochemical recurrence-free survival (BRFS), distant metastases-free survival (DMFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using Kaplan-Meier methods. Clinical outcomes, acute toxicity, and late toxicity-free survival were compared between African American and White patients with logistic regression and log-rank testing.

Results: Between November 2008 and August 2018, 143 patients with HRPC were treated with MHRT and followed for a median of 38.5 months; 82 (57%) were African American and 61 were White patients. Concurrent androgen deprivation therapy (ADT) was provided for 138 (97%) patients for a median duration of 24 months. No significant differences between African American and White patients were observed for 5-year OS (73% [95% CI, 58%-83%] vs 77% [95% CI, 60%-97%]; P = .55), PCSS (90% [95% CI, 79%-95%] vs 87% [95 % CI, 70%-95%]; P = .57), DMFS (91% [95% CI, 80%-96%] vs 81% [95% CI, 62%-91%]; P = .55), or BRFS (83% [95% CI, 70%-91%] vs 71% [95% CI, 53%-82%]; P = .57), respectively. Rates of acute grade 3+ GU and GI were low overall (4% and 1%, respectively). Late toxicities were similarly favorable with no significant differences by race.

Conclusions: Individuals with HRPC treated with MHRT in an equal access setting demonstrated favorable clinical outcomes that did not differ by race, alongside acceptable rates of acute and late toxicities.

背景:中度低分割放疗(MHRT)是一种公认的治疗局限性前列腺癌的方法;然而,针对高危前列腺癌(HRPC)和/或非裔美国患者的MHRT数据有限。我们报告了在平等获取系统中治疗的HRPC患者的临床结果和毒性概况。方法:我们确定了在美国退伍军人事务部转诊中心接受MHRT治疗的HRPC患者。排除标准包括< 12个月随访和选择性淋巴结照射。MHRT包括70 Gy / 28分或60 Gy / 20分。急性和晚期胃肠道(GI)和泌尿生殖系统(GU)毒性使用不良事件通用术语标准5.0进行分级。临床终点,包括生化无复发生存期(BRFS)、无远处转移生存期(DMFS)、总生存期(OS)和前列腺癌特异性生存期(PCSS)使用Kaplan-Meier方法进行估计。通过logistic回归和log-rank检验比较非裔美国人和白人患者的临床结果、急性毒性和晚期无毒性生存。结果:2008年11月至2018年8月,143例HRPC患者接受了MHRT治疗,随访时间中位数为38.5个月;82例(57%)为非洲裔美国人,61例为白人患者。138例(97%)患者同时接受雄激素剥夺治疗(ADT),中位持续时间为24个月。非洲裔美国人和白人患者的5年OS无显著差异(73% [95% CI, 58%-83%] vs 77% [95% CI, 60%-97%];P = 55)、电脑(90%(95%可信区间,79% - -95%)和87%(95%可信区间,70% - -95%);P = .57)、时间(91%(95%可信区间,80% - -96%)和81%(95%可信区间,62% - -91%);P = 55),或BRFS(83%(95%可信区间,70% - -91%)和71%(95%可信区间,53% - -82%);P = 0.57)。急性3+级GU和GI的发生率总体较低(分别为4%和1%)。晚期毒性同样有利,种族间无显著差异。结论:在平等准入的环境下,HRPC患者接受MHRT治疗显示出良好的临床结果,没有种族差异,以及可接受的急性和晚期毒性发生率。
{"title":"Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting.","authors":"David J Carpenter,&nbsp;Divya Natesan,&nbsp;R Warren Floyd,&nbsp;Taofik Oyekunle,&nbsp;Donna Niedzwiecki,&nbsp;Laura Waters,&nbsp;Devon Godfrey,&nbsp;Michael J Moravan,&nbsp;Rhonda L Bitting,&nbsp;Jeffrey R Gingrich,&nbsp;W Robert Lee,&nbsp;Joseph K Salama","doi":"10.12788/fp.0305","DOIUrl":"https://doi.org/10.12788/fp.0305","url":null,"abstract":"<p><strong>Background: </strong>Moderately hypofractionated radiotherapy (MHRT) is an accepted treatment for localized prostate cancer; however, limited MHRT data address high-risk prostate cancer (HRPC) and/or African American patients. We report clinical outcomes and toxicity profiles for individuals with HRPC treated in an equal access system.</p><p><strong>Methods: </strong>We identified patients with HRPC treated with MHRT at a US Department of Veterans Affairs referral center. Exclusion criteria included < 12 months follow-up and elective nodal irradiation. MHRT included 70 Gy over 28 fractions or 60 Gy over 20 fractions. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicities were graded using Common Terminology Criteria for Adverse Events, version 5.0. Clinical endpoints, including biochemical recurrence-free survival (BRFS), distant metastases-free survival (DMFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using Kaplan-Meier methods. Clinical outcomes, acute toxicity, and late toxicity-free survival were compared between African American and White patients with logistic regression and log-rank testing.</p><p><strong>Results: </strong>Between November 2008 and August 2018, 143 patients with HRPC were treated with MHRT and followed for a median of 38.5 months; 82 (57%) were African American and 61 were White patients. Concurrent androgen deprivation therapy (ADT) was provided for 138 (97%) patients for a median duration of 24 months. No significant differences between African American and White patients were observed for 5-year OS (73% [95% CI, 58%-83%] vs 77% [95% CI, 60%-97%]; <i>P</i> = .55), PCSS (90% [95% CI, 79%-95%] vs 87% [95 % CI, 70%-95%]; <i>P</i> = .57), DMFS (91% [95% CI, 80%-96%] vs 81% [95% CI, 62%-91%]; <i>P</i> = .55), or BRFS (83% [95% CI, 70%-91%] vs 71% [95% CI, 53%-82%]; <i>P</i> = .57), respectively. Rates of acute grade 3+ GU and GI were low overall (4% and 1%, respectively). Late toxicities were similarly favorable with no significant differences by race.</p><p><strong>Conclusions: </strong>Individuals with HRPC treated with MHRT in an equal access setting demonstrated favorable clinical outcomes that did not differ by race, alongside acceptable rates of acute and late toxicities.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"S35-S41"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662313/pdf/fp-39-08s-s35.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40706883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postdeployment Respiratory Health: The Roles of the Airborne Hazards and Open Burn Pit Registry and the Post-Deployment Cardiopulmonary Evaluation Network. 部署后呼吸健康:空气传播危害和露天烧伤登记以及部署后心肺评估网络的作用。
Caroline W Davis, Alexander S Rabin, Nisha Jani, John J Osterholzer, Silpa Krefft, Stella E Hines, Mehrdad Arjomandi, Michelle W Robertson, Anays M Sotolongo, Michael J Falvo

Background: Following deployment to the Southwest Asia theater of operations and Afghanistan, many service members and veterans report respiratory symptoms and concerns about their military and environmental exposures. The US Department of Veterans Affairs (VA) established the national Airborne Hazards and Open Burn Pit Registry (AHOBPR) in 2014 to help better understand long-term health conditions that may be related to these exposures.

Observations: The AHOBPR provides an online questionnaire and optional health evaluation performed by a primary care or environmental health clinician. The clinical evaluation provides an opportunity for the service member or veteran to talk with a health care professional about their symptoms, exposures, and potential treatment. Data derived from questionnaire responses and health evaluations facilitate medical surveillance and research. The VA also established a network of specialists, referred to as the Post-Deployment Cardiopulmonary Evaluation Network (PDCEN). The PDCEN identifies veterans within the AHOBPR who self-report certain conditions or have unexplained dyspnea and conducts comprehensive diagnostic evaluations. Primary objectives of PDCEN evaluations are to define respiratory and related conditions that are present, determine whether conditions are related to deployment, and work with the veteran's clinician to identify treatments and/or follow-up care to improve their health. We utilize a case example to illustrate the role of the primary care practitioner in connecting veterans to PDCEN clinical evaluations.

Conclusions: AHOBPR clinical evaluations represent an initial step to better understand postdeployment health conditions. The PDCEN clinical evaluation extends the AHOBPR evaluation by providing specialty care for certain veterans requiring more comprehensive evaluation while systematically collecting and analyzing clinical data to advance the field.

背景:在部署到西南亚战区和阿富汗后,许多服役人员和退伍军人报告呼吸道症状,并对他们的军事和环境暴露感到担忧。美国退伍军人事务部(VA)于2014年建立了国家空气传播危害和露天烧伤坑登记处(AHOBPR),以帮助更好地了解可能与这些暴露有关的长期健康状况。观察:AHOBPR提供了一份在线问卷和可选的健康评估,由初级保健或环境卫生临床医生执行。临床评估为服役人员或退伍军人提供了一个与医疗保健专业人员谈论他们的症状、暴露和潜在治疗的机会。来自调查表答复和健康评价的数据有助于医疗监测和研究。退伍军人事务部还建立了一个专家网络,称为部署后心肺评估网络(PDCEN)。PDCEN在AHOBPR中识别自我报告某些情况或有不明原因呼吸困难的退伍军人,并进行全面的诊断评估。PDCEN评估的主要目标是确定当前存在的呼吸和相关疾病,确定这些疾病是否与部署有关,并与退伍军人的临床医生合作确定治疗方法和/或后续护理,以改善他们的健康。我们利用一个案例来说明初级保健医生在将退伍军人与PDCEN临床评估联系起来方面的作用。结论:AHOBPR临床评估是更好地了解部署后健康状况的第一步。PDCEN临床评估扩展了AHOBPR评估,为某些需要更全面评估的退伍军人提供专业护理,同时系统地收集和分析临床数据,以推进该领域的发展。
{"title":"Postdeployment Respiratory Health: The Roles of the Airborne Hazards and Open Burn Pit Registry and the Post-Deployment Cardiopulmonary Evaluation Network.","authors":"Caroline W Davis,&nbsp;Alexander S Rabin,&nbsp;Nisha Jani,&nbsp;John J Osterholzer,&nbsp;Silpa Krefft,&nbsp;Stella E Hines,&nbsp;Mehrdad Arjomandi,&nbsp;Michelle W Robertson,&nbsp;Anays M Sotolongo,&nbsp;Michael J Falvo","doi":"10.12788/fp.0307","DOIUrl":"https://doi.org/10.12788/fp.0307","url":null,"abstract":"<p><strong>Background: </strong>Following deployment to the Southwest Asia theater of operations and Afghanistan, many service members and veterans report respiratory symptoms and concerns about their military and environmental exposures. The US Department of Veterans Affairs (VA) established the national Airborne Hazards and Open Burn Pit Registry (AHOBPR) in 2014 to help better understand long-term health conditions that may be related to these exposures.</p><p><strong>Observations: </strong>The AHOBPR provides an online questionnaire and optional health evaluation performed by a primary care or environmental health clinician. The clinical evaluation provides an opportunity for the service member or veteran to talk with a health care professional about their symptoms, exposures, and potential treatment. Data derived from questionnaire responses and health evaluations facilitate medical surveillance and research. The VA also established a network of specialists, referred to as the Post-Deployment Cardiopulmonary Evaluation Network (PDCEN). The PDCEN identifies veterans within the AHOBPR who self-report certain conditions or have unexplained dyspnea and conducts comprehensive diagnostic evaluations. Primary objectives of PDCEN evaluations are to define respiratory and related conditions that are present, determine whether conditions are related to deployment, and work with the veteran's clinician to identify treatments and/or follow-up care to improve their health. We utilize a case example to illustrate the role of the primary care practitioner in connecting veterans to PDCEN clinical evaluations.</p><p><strong>Conclusions: </strong>AHOBPR clinical evaluations represent an initial step to better understand postdeployment health conditions. The PDCEN clinical evaluation extends the AHOBPR evaluation by providing specialty care for certain veterans requiring more comprehensive evaluation while systematically collecting and analyzing clinical data to advance the field.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":"39 8","pages":"337-343"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652027/pdf/fp-39-08-337.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10002408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non-Small Cell Lung Cancer: A Meta-analysis. 突变型EGFR-TK抑制剂治疗晚期非小细胞肺癌的安全性:一项荟萃分析
Pub Date : 2022-08-01 Epub Date: 2022-08-13 DOI: 10.12788/fp.0309
Abubakar Tauseef, Maryam Zafar, Peter Silberstein, Joseph Nahas, Thomas Frederickson, Sean Hansen, Anum Abbas, Yaman Alali, Avdesh Buragadda, Omar K Abughanimeh, Sunil Nair, Joseph Thirumalareddy, Mohsin Mirza

Background: Despite the use of platinum-based chemotherapy, lung cancer continues to be the leading cause of cancer-related death in the world. To overcome the rate of lung cancer-related death, scientists discovered advanced therapies, including mutant epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors.

Observations: We conducted a meta-analysis to determine the safety profile of mutant EGFR-TK inhibitors in the management of advanced non-small cell lung cancer (NSCLC). Included in this study are 9 phase 3 randomized controlled trials designed to study the safety profile of mutant EGFR-TK inhibitors in patients with advanced NSCLC. The study showed that mutant EGFR-TK inhibitors have an incidence of adverse effects that is less reported when compared with platinum-based chemotherapy.

Conclusions: We recommend continuing using mutant EGFR-TK inhibitors in patients with advanced NSCLC especially in patients having mutant EGFR receptors. Adverse effects caused by mutant EGFR-TK inhibitors are significant but are usually tolerable and can be avoided by reducing the dosage of it with each cycle or by skipping or delaying the dose until patient is symptomatic.

背景:尽管使用了铂基化疗,肺癌仍然是世界上癌症相关死亡的主要原因。为了克服肺癌相关的死亡率,科学家们发现了先进的治疗方法,包括突变的表皮生长因子受体酪氨酸激酶(EGFR-TK)抑制剂。观察:我们进行了一项荟萃分析,以确定突变型EGFR-TK抑制剂在晚期非小细胞肺癌(NSCLC)治疗中的安全性。本研究包括9项3期随机对照试验,旨在研究突变型EGFR-TK抑制剂在晚期NSCLC患者中的安全性。研究表明,与铂基化疗相比,突变型EGFR-TK抑制剂的不良反应发生率较少。结论:我们建议在晚期NSCLC患者中继续使用突变型EGFR- tk抑制剂,特别是在EGFR受体突变的患者中。突变型EGFR-TK抑制剂引起的不良反应是显著的,但通常是可耐受的,可以通过减少每个周期的剂量或跳过或延迟剂量直至患者出现症状来避免。
{"title":"Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non-Small Cell Lung Cancer: A Meta-analysis.","authors":"Abubakar Tauseef,&nbsp;Maryam Zafar,&nbsp;Peter Silberstein,&nbsp;Joseph Nahas,&nbsp;Thomas Frederickson,&nbsp;Sean Hansen,&nbsp;Anum Abbas,&nbsp;Yaman Alali,&nbsp;Avdesh Buragadda,&nbsp;Omar K Abughanimeh,&nbsp;Sunil Nair,&nbsp;Joseph Thirumalareddy,&nbsp;Mohsin Mirza","doi":"10.12788/fp.0309","DOIUrl":"https://doi.org/10.12788/fp.0309","url":null,"abstract":"<p><strong>Background: </strong>Despite the use of platinum-based chemotherapy, lung cancer continues to be the leading cause of cancer-related death in the world. To overcome the rate of lung cancer-related death, scientists discovered advanced therapies, including mutant epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitors.</p><p><strong>Observations: </strong>We conducted a meta-analysis to determine the safety profile of mutant EGFR-TK inhibitors in the management of advanced non-small cell lung cancer (NSCLC). Included in this study are 9 phase 3 randomized controlled trials designed to study the safety profile of mutant EGFR-TK inhibitors in patients with advanced NSCLC. The study showed that mutant EGFR-TK inhibitors have an incidence of adverse effects that is less reported when compared with platinum-based chemotherapy.</p><p><strong>Conclusions: </strong>We recommend continuing using mutant EGFR-TK inhibitors in patients with advanced NSCLC especially in patients having mutant EGFR receptors. Adverse effects caused by mutant EGFR-TK inhibitors are significant but are usually tolerable and can be avoided by reducing the dosage of it with each cycle or by skipping or delaying the dose until patient is symptomatic.</p>","PeriodicalId":73021,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":" ","pages":"S72-S80"},"PeriodicalIF":0.0,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662311/pdf/fp-39-08s-s72.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40706881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1